Details of the Drug

General Information of Drug (ID: DMVRH9C)

• Drug Name: Lomefloxacin
• Synonyms: LFLX; Lomefloxacine; Lomefloxacino; Lomefloxacinum; Lomefloxacine [French]; Lomefloxacino [Spanish]; Lomefloxacinum[Latin]; SC 4711; SC 47111A; DM 10 (bactericide); DM-10; Lomefloxacin (USAN); Maxaquin (TN); Maxaquin (hydrochloride); Okacyn (TN); SC-4711; SC-47111A; Uniquin (TN); Lomefloxacin [USAN:BAN:INN]; NY-198 (hydrochloride); SC-47111 (hydrochloride); SC-47111B (mesylate); (+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid; 3-Quinolinecarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-, monohydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]

• Therapeutic Class: Antibiotics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 351.35
  Topological Polar Surface Area (xlogp); -0.8
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [2]
  Bioavailability: 97% of drug becomes completely available to its intended biological destination(s) [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 3.98 mL/min/kg [4]
  Elimination: 65% of drug is excreted from urine in the unchanged form [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 8 hours [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 16.2633 micromolar/kg/day [5]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.04 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 1.64 mg/mL [2]
• Chemical Identifiers:
  Formula: C17H19F2N3O3
  IUPAC Name: 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
  Canonical SMILES: CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O
  InChI: InChI=1S/C17H19F2N3O3/c1-3-21-8-11(17(24)25)16(23)10-6-12(18)15(13(19)14(10)21)22-5-4-20-9(2)7-22/h6,8-9,20H,3-5,7H2,1-2H3,(H,24,25)
  InChIKey: ZEKZLJVOYLTDKK-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 3948
  ChEBI ID: CHEBI:116278
  CAS Number: 98079-51-7
  DrugBank ID: DB00978
  TTD ID: D02KOF
  VARIDT ID: DR00507
  INTEDE ID: DR0968

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 1A2 (CYP1A2) Main DME	DEJGDUW	CP1A2_HUMAN	Substrate	[8]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lomefloxacin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Lomefloxacin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[35]

Coadministration of a Drug Treating the Disease Different from Lomefloxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[36]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Midostaurin.	Acute myeloid leukaemia [2A60]	[35]
Idarubicin	DMM0XGL	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Idarubicin.	Acute myeloid leukaemia [2A60]	[37]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Arn-509.	Acute myeloid leukaemia [2A60]	[38]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[39]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Oliceridine.	Acute pain [MG31]	[40]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Rivastigmine.	Alzheimer disease [8A20]	[35]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Ivabradine.	Angina pectoris [BA40]	[38]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Dronedarone.	Angina pectoris [BA40]	[35]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[41]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Cilostazol.	Arterial occlusive disease [BD40]	[35]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Posaconazole.	Aspergillosis [1F20]	[35]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Levalbuterol.	Asthma [CA23]	[42]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Pirbuterol.	Asthma [CA23]	[42]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Salbutamol.	Asthma [CA23]	[42]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Formoterol.	Asthma [CA23]	[43]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[38]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[35]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Retigabine.	Behcet disease [4A62]	[40]
Lomustine	DMMWSUL	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[37]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Eribulin.	Breast cancer [2C60-2C6Y]	[35]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lapatinib.	Breast cancer [2C60-2C6Y]	[35]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[37]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Bosutinib.	Breast cancer [2C60-2C6Y]	[38]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[44]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[42]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[43]
Ketoprofen	DMRKXPT	Moderate	Additive CNS depression effects by the combination of Lomefloxacin and Ketoprofen.	Chronic pain [MG30]	[45]
Capecitabine	DMTS85L	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Capecitabine.	Colorectal cancer [2B91]	[37]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Isoproterenol.	Conduction disorder [BC63]	[42]
Mestranol	DMG3F94	Moderate	Decreased absorption of Lomefloxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[46]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Halothane.	Corneal disease [9A76-9A78]	[35]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Sevoflurane.	Corneal disease [9A76-9A78]	[35]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Lomefloxacin due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[47]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Pasireotide.	Cushing syndrome [5A70]	[35]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Osilodrostat.	Cushing syndrome [5A70]	[36]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Sertraline.	Depression [6A70-6A7Z]	[35]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Escitalopram.	Depression [6A70-6A7Z]	[35]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Clomipramine.	Depression [6A70-6A7Z]	[35]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Doxepin.	Depression [6A70-6A7Z]	[35]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[35]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Deutetrabenazine.	Dystonic disorder [8A02]	[48]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Ingrezza.	Dystonic disorder [8A02]	[49]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Solifenacin.	Functional bladder disorder [GC50]	[35]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Ketoconazole.	Fungal infection [1F29-1F2F]	[35]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[35]
Procarbazine	DMIK367	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[37]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[52]
Iron	DMAP8MV	Moderate	Decreased absorption of Lomefloxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[53]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Lomefloxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[35]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Crizotinib.	Lung cancer [2C25]	[54]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Ceritinib.	Lung cancer [2C25]	[35]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[37]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Osimertinib.	Lung cancer [2C25]	[55]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Selpercatinib.	Lung cancer [2C25]	[56]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lumefantrine.	Malaria [1F40-1F45]	[57]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Hydroxychloroquine.	Malaria [1F40-1F45]	[58]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Primaquine.	Malaria [1F40-1F45]	[35]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[38]
Fludarabine	DMVRLT7	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[37]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[59]
Mercaptopurine	DMTM2IK	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Mercaptopurine.	Mature B-cell lymphoma [2A85]	[37]
Cytarabine	DMZD5QR	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Cytarabine.	Mature B-cell lymphoma [2A85]	[37]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Vemurafenib.	Melanoma [2C30]	[35]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and LGX818.	Melanoma [2C30]	[60]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Lomefloxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[35]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Panobinostat.	Multiple myeloma [2A83]	[61]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Thalidomide.	Multiple myeloma [2A83]	[57]
Melphalan	DMOLNHF	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Melphalan.	Multiple myeloma [2A83]	[37]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Siponimod.	Multiple sclerosis [8A40]	[57]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Fingolimod.	Multiple sclerosis [8A40]	[35]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Lomefloxacin and Ozanimod.	Multiple sclerosis [8A40]	[62]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Deflazacort.	Muscular dystrophy [8C70]	[63]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Romidepsin.	Mycosis fungoides [2B01]	[40]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[64]
Hydroxyurea	DMOQVU9	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[37]
Busulfan	DMXYJ9C	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Busulfan.	Myeloproliferative neoplasm [2A20]	[37]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Promethazine.	Nausea/vomiting [MD90]	[35]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Lomefloxacin and Bupropion.	Nicotine use disorder [6C4A]	[65]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Entrectinib.	Non-small cell lung cancer [2C25]	[38]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lofexidine.	Opioid use disorder [6C43]	[35]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Rucaparib.	Ovarian cancer [2C73]	[35]
Topotecan	DMP6G8T	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Topotecan.	Ovarian cancer [2C73]	[37]
Ibuprofen	DM8VCBE	Moderate	Additive CNS depression effects by the combination of Lomefloxacin and Ibuprofen.	Pain [MG30-MG3Z]	[45]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Triclabendazole.	Parasitic worm infestation [1F90]	[40]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Pimavanserin.	Parkinsonism [8A00]	[66]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[67]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lefamulin.	Pneumonia [CA40]	[36]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Lomefloxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[68]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Degarelix.	Prostate cancer [2C82]	[38]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and ABIRATERONE.	Prostate cancer [2C82]	[38]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Enzalutamide.	Prostate cancer [2C82]	[38]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Bicalutamide.	Prostate cancer [2C82]	[38]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Lomefloxacin and Salsalate.	Rheumatoid arthritis [FA20]	[45]
Oxaprozin	DM9UB0P	Moderate	Additive CNS stimulant effects by the combination of Lomefloxacin and Oxaprozin.	Rheumatoid arthritis [FA20]	[45]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Lomefloxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[63]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Quetiapine.	Schizophrenia [6A20]	[35]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Aripiprazole.	Schizophrenia [6A20]	[57]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Iloperidone.	Schizophrenia [6A20]	[35]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Paliperidone.	Schizophrenia [6A20]	[35]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Amisulpride.	Schizophrenia [6A20]	[69]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Asenapine.	Schizophrenia [6A20]	[35]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Pimozide.	Schizophrenia [6A20]	[38]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[37]
Docetaxel	DMDI269	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[37]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[37]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[35]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[35]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[38]
Taxol	DMUOT9V	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[37]
Doxorubicin	DMVP5YE	Minor	Decreased absorption of Lomefloxacin due to intestinal mucosa variation caused by Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[37]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Pitolisant.	Somnolence [MG42]	[35]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[35]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Lenvatinib.	Thyroid cancer [2D10]	[35]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Cabozantinib.	Thyroid cancer [2D10]	[38]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Papaverine.	Tonus and reflex abnormality [MB47]	[70]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[71]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[35]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Lomefloxacin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[35]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Lomefloxacin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[71]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020013.
• [2] BDDCS applied to over 900 drugs
• [3] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
• [7] Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
• [8] Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother. 1992 May;36(5):942-8.
• [9] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [10] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [11] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [12] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [13] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [14] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [15] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [16] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [17] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [18] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [19] Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
• [20] Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
• [21] Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
• [22] Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
• [23] Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
• [24] Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
• [25] Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
• [26] Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
• [27] Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
• [28] Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
• [29] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [30] Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
• [31] Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
• [32] Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
• [33] Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
• [34] Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
• [35] Canadian Pharmacists Association.
• [36] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [37] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [38] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [39] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [40] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
• [41] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [42] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [43] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [44] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [45] Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
• [46] Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
• [47] Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
• [48] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [49] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [50] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [51] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [52] Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
• [53] Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
• [54] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [55] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [56] Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
• [57] Cerner Multum, Inc. "Australian Product Information.".
• [58] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [59] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [60] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [61] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [62] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [63] FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
• [64] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [65] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [66] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [67] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [68] Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
• [69] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [70] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [71] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]